T ranscatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve replacement in patients deemed high risk or extreme risk for surgery.
measurements have been recommended, the latter providing larger dimensions in the setting of eccentricity. 17 Prior study has shown that undersizing of the THV may result in higher degrees of paravalvular aortic regurgitation (PVR) after balloon-expandable TAVR. [11] [12] [13] The self-expanding CoreValve THV differs from the balloon-expandable THV in that the CoreValve THV conforms to the native annulus, providing continuous outward radial force to the noncircular annulus. 6 Serial echocardiographic studies have shown a reduction in the degree of PVR over the year after CoreValve TAVR, 1, 3 potentially because of long-term annular remodeling. A sizing chart has been developed to guide the selection of the CoreValve THV using aortic annular measurements (Table 1) , but this sizing algorithm has not been validated in clinical practice. The purpose of this study was to assess the effect of compliance with commercial sizing recommendations using MDCT on clinical outcomes after CoreValve TAVR and to assess the relationship between the device annular sizing ratio (DAR) and the occurrence of PVR after CoreValve TAVR.
Methods

Patient Selection
Patients included in this analysis were enrolled in the CoreValve US Extreme Risk 3 or High Risk 1 Pivotal Trials at 45 clinical sites in the United States. Inclusion and exclusion criteria have been reported in detail elsewhere. 1, 3 In brief, patients with New York Heart Association class II or greater symptoms were eligible. 1, 3 Extreme-risk patients were considered to have a surgical risk of death or majority morbidity ≥50% at 30 days, 3 whereas high-risk patients were considered to have a >15% surgical mortality rate at 30 days. 1 Severe aortic stenosis was defined as an aortic valve area ≤0.8 cm 2 or aortic valve index ≤0.5 cm 2 /m 2 and either a mean aortic valve gradient >40 mm Hg or a peak aortic valve velocity >4.0 m/s at rest or with dobutamine. 1, 3 Principal exclusion criteria were a gastrointestinal hemorrhage within the prior 3 months, a major stroke within the prior 6 months, or a life expectancy <1 year because of comorbidities. Anatomic exclusion criteria included an aortic annular diameter <18 mm or >29 mm. 1, 3 The responsible institutional review boards approved the study protocols, and written informed consent was obtained from all patients before enrollment. The trial was conducted in accordance with the International Conference on Harmonization, Good Clinical Practice Guidelines, and the Declaration of Helsinki.
Multidetector Computed Tomography Angiography
All patients considered for inclusion in these studies underwent MDCT angiography (64-slice minimum) with retrospective electrocardiographic gating. All images were forwarded to a central analysis laboratory for review by independent observers who were unaware of the THV sizes used or the clinical outcomes. Best systolic images selected from the 30% or 40% phase were used for analysis, whenever possible. 18 MDCT images were analyzed using 3Mensio software (Pie Medical, Maastricht, The Netherlands), which provided a centerline reconstruction of the aortovalvular complex, including the proximal ascending aorta, aortic root, aortic annulus, and left ventricular outflow tract; a user-defined designation of the inferior basal position of the right coronary sinus, left coronary sinus, and noncoronary sinus; realignment of the centerline to provide a perpendicular image of the basal aortic annulus; and measurement tools to provide a maximum diameter, diameter perpendicular to the maximal diameter, and a polygon aortic valve perimeter 19 ( Figure 1 ). Below-range (undersize THV) sizing was defined when annular perimeters (diameters) were larger than the recommended window; in-range sizing was defined when annular perimeters (diameters) were within the recommended window; aboverange (oversized THV) sizing was defined as those annular perimeters (diameters) that were smaller than the recommended window (Table 1) .
A DAR was determined by the following: DAR=[(Valve perimeter-annulus perimeter)/annular perimeter] ×100.
CoreValve THV Sizing
CoreValve THV sizing was based on clinical site readings of the preenrollment MDCT (Table 1) . This report includes 23-, 26-, 29-, and 31-mm-diameter THVs treating patients with an annulus range from 18 to 29 mm. Only the 26-and 29-mm CoreValve devices were available early in the clinical study; the 26-mm valve was recommended for annular diameters from 20 to 23 mm, and the 29-mm valve was recommended for annular diameters between 23 and 27 mm. When available, the 31-mm valve size was recommended for annular diameters from 26 to 29 mm. Commercial sizing recommendations in the instructions for use differ slightly from those of the clinical protocol, which restricted the use of the 29-mm CoreValve to annular diameters of 23 to 26 mm (Table 1 ). For purposes of this analysis, the DAR was based on the THV size at the inflow of the device.
Procedural Details
The procedure has been described in detail elsewhere. 1, 3 The self-expanding THV was ideally positioned such that the inflow portion of the frame
WHAT IS KNOWN
• Residual aortic regurgitation is a recognized complication during transcatheter aortic valve replacement in patients with severe aortic stenosis.
• Transcatheter heart valve sizing using 3-dimensional preprocedural imaging has been shown to reduce the frequency of residual aortic regurgitation during transcatheter aortic valve replacement.
WHAT THE STUDY ADDS
• We showed that higher (≥15%) device artery ratios based on perimeter-based diameters using multidetector computed tomographic imaging were associated with lower rates of residual aortic regurgitation without an increase in procedural complications.
• Multidetector computer tomographic images should be used for self-expanding transcatheter heart valve size selection in patients undergoing treatment of severe aortic stenosis. Data presented as ranges. CT indicates computed tomography; and THV, transcatheter heart valve. was 4 to 6 mm inferior to the noncoronary basal annulus. After valve deployment, valve performance was evaluated using transthoracic or transesophageal echocardiography, aortography, and invasive measurements of transaortic valve gradients and left ventricular end-diastolic pressures. Postdilatation was recommended in the event of moderate or severe PVR using these parameters because of incomplete frame expansion.
Echocardiographic Analysis
The PVR was graded in the Mayo Clinic Core Laboratory based on multiple parameters, including regurgitation color jet density and width, circumferential extent of turbulent regurgitation color jet around the aortic annulus for paravalvular regurgitation, descending and abdominal aorta diastolic flow reversal on pulsed wave Doppler, and pressure half time of aortic regurgitation continuous wave Doppler signal. When there was discordance regarding the severity of PVR among above parameters, color flow imaging was the first priority in the hierarchy of determining its severity as follows: trivial regurgitation when there is a trace of short-lasting (less than the entire diastole) with or without a dot of regurgitation jet around the aortic annulus; mild regurgitation where the circumferential extent is <10% with turbulent aortic regurgitation jet; moderate regurgitation when the circumferential extent is 10% to 20%; and severe regurgitation when the circumferential extent is >20%.
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Clinical Outcomes
Clinical events included all-cause death, myocardial infarction, all stroke, reintervention to alter, adjust, or replace a previously implanted valve, and implantation of a permanent pacemaker. Symptom status was assessed using the New York Heart Association classification system. Device success, cardiovascular death, and major and minor stroke were defined using Valve Academic Research Consortium-1 criteria.
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Statistical Analysis
Extreme-and high-risk patients who received successful TAVR are included in the analysis. Categorical variables were compared with the use of the Fisher exact test or the χ 2 test, as appropriate. Continuous variables were presented as means (±SD) and compared with the use of Student's t test or the analysis of variance, as appropriate. Kaplan-Meier estimates were used for the timeto-event analysis and were compared using the log-rank test. All testing used a 2-sided alpha level of 0.05. All statistical analyses were performed with the use of SAS software, version 9.2 (SAS Institute, Cary, NC).
Results
Clinical and MDCT Findings
The clinical demographics of extreme-and high-risk patients included in this analysis are found in Table 2 . The MDCTbased annular diameters, areas, and perimeters by valve size are found in Table 3 . The mean diameters and perimeters increased based on the CoreValve THV size deployed. The mean perimeter-derived diameters were slightly larger than the mean measured diameters. The mean eccentricity ratio was 1.3 and did not vary by THV size selected.
Perimeter DARs are also found in Table 3 . The mean perimeter-derived DAR was slightly higher for the 23-mm (15.2%), 26-mm (16.9%), and 29-mm (15.4%) THV than for the 31-mm THV (12.5%). The relationship between annular sizing ratio and PVR is found in Figure 2 . There was subjectively less moderate or severe PVR when a larger valve was implanted in perimeterbased diameter annular ranges for 23-and 26-mm diameters (Figure 3) . Compared with the algorithm recommendations, inrange THV selection ranged from 38.5% for the 23-mm THV to 92.6% for the 31-mm THV. Below-range perimeter-based DARs were found more often with the 23-mm THV (57.7%) than with the 31-mm THV (4.3%; Table 4 ).
Clinical Outcomes
There were no differences in death, stroke, or myocardial infarction based on compliance with in-range or out-of-range valve selection (Table 5 ). There tended to be more moderate or severe PVR in patients with a below-range ratio (15.3%) than in patients with in-window valve selection (6.5%) and high sizing ratio (10.0%; P<0.001; Table 5 ). There also tended to be a greater need for balloon postdilatation in patients with a below-range sizing (26.4%) compared with patients with in-range (17.5%) or above-range (9.1%) sizing. There were no differences in the need for a second valve or the need for permanent pacemakers based on the in-range or out-of-range sizing (Table 5 ).
There were also no differences in major clinical events in patients based on the DAR (Table 6 ). There was an inverse relationship between the DAR and discharge moderate or severe PVR: DAR ≤10%, 17.6%; DAR 10% to 15%, 9.9%; DAR 15% to 20%, 6.3%, and DAR >20%, 4.9%; P<0.001; Table 6 ). There was also an inverse relationship between the DAR and need for postdilatation (Figure 4 ). There was no relationship with annular sizing ratios and the need for a second valve, valve-in-valve, or permanent pacemaker implantation (Table 6 ). The annular sizing ratio was higher in patients who had none or trivial PVR at both discharge and 1 year (16.9%) and in patients with mild or greater PVR at discharge who regressed to none or trivial PVR by 1 year (15.6%) than in patients who had mild or greater PVR at 1 year (14.3%; P<0.001; Figure 5 ).
Discussion
We found that adherence to the recommended annular sizing guidelines based on a standardized assessment of the MDCT aortic annular measures resulted in favorable clinical outcomes after placement of self-expanding CoreValve THV. In-range CoreValve THV sizing was associated with lower rates of moderate or severe PVR and a lower need for balloon postdilation after THV placement than below-range sizing. We identified an inverse relationship with DARs and PVR, with the highest DAR having the lowest rates of moderate or severe PVR at discharge. We also found higher DARs in patients who developed reductions in the degree of PVR over time compared with those without changes in PVR. There was no significant risk for complications associated with higher DARs. These findings have important implications for device sizing with the self-expanding CoreValve THV and underscore the need for 3-dimensional imaging of the aortic annulus for THV size selection, particularly for the CoreValve self-expanding THV.
Value of MDCT for Annular Sizing
Two-dimensional imaging using echocardiography underestimates the true annular dimensions in patients undergoing TAVR, owing to the eccentric morphology of the native annulus. 21, 22 As a result, transcatheter valve selection based on 2-dimensional imaging has resulted in the selection of THVs that are relatively undersized to the true aortic annulus, 10 potentially resulting in postdeployment PVR. [7] [8] [9] 13 Although 3-dimensional transesophageal echocardiography may provide a better estimate of the annular dimensions, 23 MDCT is now considered the reference standard for THV sizing for both the balloon-expandable 8, 11 and self-expanding 15, 24, 25 designs. A number of parameters, including area, 8 mean diameter, 10,11 and perimeter, 6 have been used to estimate annular dimensions and to guide approximate THV sizing. We selected annular perimeterbased diameters as the best measure for CoreValve sizing.
Each study site used its own MDCT readings to determine CoreValve THV sizing. Current commercial label recommendations for CoreValve sizing are similar to those in the clinical study used for this analysis, except that the recommendation for the 29-mm CoreValve was restricted to perimeter-based diameters of 23 to 26 mm rather than 23 to 27 mm for the clinical study. It is interesting to note that the clinical sites selected a belowrange CoreValve in 28.8% of cases for the 26-mm CoreValve and 26.9% for the 29-mm CoreValve. A number of factors may have contributed to undersizing of the CoreValve THV by the clinical sites, including variability with MDCT readings, other anatomic findings, such as valvular calcification, 26 narrow sinus of Valsalva diameters, or functional bicuspid valve morphology, and general concerns about potential complications of oversizing, such as pacemaker requirements and annular rupture. Although we found no difference in major clinical events with in-range and out-ofrange THV sizing, we found significantly lower rates of moderate or severe PVR in patients with in-range THV sizing (6.5% versus 15.3% with below-range sizing; P<0.001) without increasing the requirement for new permanent pacemakers (20.9% versus 18.1% in patients with below-range sizing; P=NS). Data presented as N (%). Annular Sizing With TAVR
Device Annular Sizing Ratio
Binder et al found that modest oversizing of 5% to 10% of area measurements resulted in lower rates (5.3%) of more than mild PVR compared with relative undersizing (12.8% in the control group; P=0.032) after balloon-expandable TAVR 8 ; others have shown similar findings using a cover index (or interference) defined as the [(valve diameter−annular diameter)/valve diameter×100] using 2-dimensional echocardiography. 27 We found an inverse relationship between the device annular ratio and the occurrence of moderate or severe PVR after CoreValve placement in our study. The frequency of moderate or severe PVR was 17.6% in patients treated with a DAR ≤10%, whereas it was 4.9% in patients with a DAR >20% (P<0.001). This finding has important implications for borderline perimeters when either a large or smaller device can be selected. For example, in patients with an annular perimeter-based diameter of 23 mm, selection of a 29-mm THV will result in a lower rate of PVR than selection of a 26-mm THV (Figure 3) . Similarly, in patients with an annular perimeter-based diameter of 26 mm, selection of a 31-mm THV will have lower rates of PVR than selection of a 29-mm THV ( Figure 3) .
We also found lower rates of the need for balloon postdilatation for residual PVR in patients with larger DARs ( Figure  4 ). Although we found no significant differences in the need for a permanent pacemaker based on the DAR, larger studies are needed to fully examine the relationship between oversizing and conduction system disturbances.
Temporal Reduction in Paravalvular Regurgitation
The CoreValve US Extreme Risk and High Risk Pivotal Trials have demonstrated a reduction in the severity of moderate PVR from discharge to 1 year on serial echocardiographic analysis by an independent core laboratory. 1, 3 We found higher DARs in patients with none or trivial PVR at discharge and 1 year 
Limitations
This analysis focused on patients treated in the Extreme Risk and High Risk Pivotal Trials. The 31-mm CoreValve was not available until later in the study, and the percentages of current valve size use suggest that the 31-mm CoreValve is used in ≤38% of cases (Medtronic, internal marketing information). It is also important to recognize the important relationship between DAR and the depth of implantation. The CoreValve frame has a tapering from the inflow to the constrained area of the valve. Our DAR includes the nominal diameter of the frame at its inflow; deeper implants will have lower DAR, particularly for implantation of the 31-mm CoreValve THV. We did not account for the depth of implantation in this analysis because THV size selection is performed before the procedure. There are also a number of other determinates of PVR, such as annular and valvular calcification. 28 This analysis did not include consideration of the effect of aortic calcium on valvular regurgitation.
Our study shows an important relationship between the annular sizing by MDCT and the occurrence of moderate or severe PVR in patients undergoing CoreValve TAVR. In borderline cases, selection of a larger CoreValve THV may result in lower rates of PVR and need for balloon postdilation without an increase in overall clinical events. 
